SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
| x | QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended December 31, 2003
or
| ¨ | TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT |
For the transition period from to
Commission File Number 1-15445
DRUGMAX, INC.,
(Formerly DrugMax.com, Inc.)
(Exact name of registrant as specified in its charter)
| NEVADA | 34-1755390 | |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
25400 US Highway 19 North, Suite 137, Clearwater, FL 33763
(Address of principal executive offices)
(727) 533-0431
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12-b-2 of the Exchange Act.) ¨ Yes x No.
As of February 13, 2004 there were 7,185,642 shares of common stock, par value $0.001 per share, outstanding.
DRUGMAX, INC. AND SUBSIDIARIES
FORM 10-Q
FOR THE QUARTER ENDED DECEMBER 31, 2003
| Page # | ||
| PART I FINANCIAL INFORMATION |
||
| Item 1. Financial Statements |
||
|
Condensed Consolidated Balance Sheets |
3 | |
| 4 | ||
| 5 | ||
| Notes to Condensed Consolidated Financial Statements (unaudited) |
7 | |
| Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations |
13 | |
| 19 | ||
| Item 3. Quantitative and Qualitative Disclosures About Market Risk |
19 | |
| Item 4. Controls and Procedures |
19 | |
| PART II OTHER INFORMATION |
||
| Item 1. Legal Proceedings |
20 | |
| 21 | ||
| Item 6. Exhibits and Reports on Form 8-K |
22 | |
| 25 | ||
| Exhibit 31.1 Certification of Principal Executive Officer Pursuant to Section 302 |
||
| Exhibit 31.2 Certification of Principal Financial Officer Pursuant to Section 302 |
||
| Exhibit 32.1 Certification Pursuant to Section 906 |
||
| Exhibit 32.2 Certification Pursuant to Section 906 |
||
2
PART I FINANCIAL INFORMATION
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DRUGMAX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
| December 31, 2003 |
March 31, 2003 |
|||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 166,900 | $ | 161,489 | ||||
| Restricted cash |
| 2,000,000 | ||||||
| Accounts receivable, net of allowance for doubtful accounts of $1,247,468 and $1,253,826 |
13,624,445 | 11,339,842 | ||||||
| Inventory |
16,153,678 | 19,458,940 | ||||||
| Due from affiliates |
| 10,470 | ||||||
| Deferred income tax asset |
668,294 | 668,294 | ||||||
| Prepaid expenses and other current assets |
1,652,004 | 1,079,740 | ||||||
| Total current assets |
32,265,321 | 34,718,775 | ||||||
| Property and equipment, net |
1,163,268 | 767,550 | ||||||
| Goodwill |
13,105,000 | 13,105,000 | ||||||
| Patents and trademarks |
129,718 | | ||||||
| Notes receivable |
496,172 | 625,329 | ||||||
| Stockholders notes receivable |
21,277 | 100,000 | ||||||
| Net deferred income tax asset - long-term |
749,336 | 749,336 | ||||||
| Deferred financing costs, net |
425,207 | 78,912 | ||||||
| Other assets |
135,202 | 95,660 | ||||||
| Deposits |
85,291 | 33,561 | ||||||
| Total assets |
$ | 48,575,792 | $ | 50,274,123 | ||||
| LIABILITIES AND STOCKHOLDERS EQUITY | ||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 9,586,174 | $ | 14,619,341 | ||||
| Accrued expenses and other current liabilities |
350,202 | 415,065 | ||||||
| Credit line payable |
19,857,960 | 15,943,619 | ||||||
| Current portion of long-term liabilities |
215,632 | 470,176 | ||||||
| Due to affiliates |
| 4,377 | ||||||
| Total current liabilities |
30,009,968 | 31,452,578 | ||||||
| Long-term debt and capital leases |
184,073 | 35,847 | ||||||
| Other long-term liabilities |
| 501,561 | ||||||
| Total liabilities |
30,194,041 | 31,989,986 | ||||||
| Stockholders equity: |
||||||||
| Preferred stock, $.001 par value, 2,000,000 shares authorized; no preferred shares issued or outstanding |
| | ||||||
| Common stock, $.001 par value; 24,000,000 shares authorized; 7,178,976 shares issued and outstanding |
7,177 | 7,120 | ||||||
| Additional paid-in capital |
41,058,727 | 40,967,355 | ||||||
| Accumulated deficit |
(22,684,153 | ) | (22,690,338 | ) | ||||
| Total stockholders equity |
18,381,751 | 18,284,137 | ||||||
| Total liabilities and stockholders equity |
$ | 48,575,792 | $ | 50,274,123 | ||||
See accompanying notes to condensed consolidated financial statements.
3
DRUGMAX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
| For the Three Months Ended December 31, 2003 |
For the Three Months Ended December 31, 2002 |
For the Nine Months Ended December 31, 2003 |
For the Nine Months Ended December 31, 2002 |
|||||||||||||
| Revenues |
$ | 50,245,129 | $ | 85,233,822 | $ | 171,093,405 | $ | 222,073,763 | ||||||||
| Cost of goods sold |
48,177,875 | 83,350,640 | 164,903,388 | 215,929,273 | ||||||||||||
| Gross profit |
2,067,254 | 1,883,182 | 6,190,017 | 6,144,490 | ||||||||||||
| Selling, general and administrative expenses |
1,742,947 | 1,596,674 | 5,305,999 | 5,972,536 | ||||||||||||
| Amortization expense |
| | | 18,000 | ||||||||||||
| Depreciation expense |
61,325 | 72,517 | 167,791 | 220,048 | ||||||||||||
| Goodwill impairment loss |
| | | 12,468,212 | ||||||||||||
| Total operating expenses |
1,804,272 | 1,669,191 | 5,473,790 | 18,678,796 | ||||||||||||
| Operating income (loss) |
262,982 | 213,991 | 716,227 | (12,534,306 | ) | |||||||||||
| Other income (expense) |
||||||||||||||||
| Interest income |
8,979 | 33,045 | 27,514 | 72,659 | ||||||||||||
| Other income |
2,562 | 14,413 | 459,595 | 39,408 | ||||||||||||
| Interest expense |
(269,402 | ) | (226,263 | ) | (1,197,151 | ) | (806,583 | ) | ||||||||
| Total other income (expense) |
(257,861 | ) | (178,805 | ) | (710,042 | ) | (694,516 | ) | ||||||||
| Income (loss) before income tax provision and minority interest |
5,121 | 35,186 | 6,185 | (13,228,822 | ) | |||||||||||
| Income tax provision |
| (24,853 | ) | | 368,935 | |||||||||||
| Minority interest |
2,162 | | 2,162 | | ||||||||||||
| Net income (loss) |
$ | 7,283 | $ | 10,333 | $ | 8,347 | $ | (12,859,887 | ) | |||||||
| Net income (loss) per common share - basic |
$ | 0.00 | $ | 0.00 | $ | 0.00 | $ | (1.81 | ) | |||||||
| Net income (loss) per common share - diluted |
$ | 0.00 | $ | 0.00 | $ | 0.00 | $ | (1.81 | ) | |||||||
| Weighted average shares outstanding - basic |
7,178,976 | 7,160,938 | 7,160,938 | 7,119,172 | ||||||||||||
| Weighted average shares outstanding - diluted |
7,388,704 | 7,281,265 | 7,276,983 | 7,119,172 | ||||||||||||
See accompanying notes to condensed consolidated financial statements.
4
DRUGMAX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
| For the Nine Months Ended December 31, 2003 |
For the Nine Months Ended December 31, 2002 |
|||||||
| Cash flows from operating activities: |
||||||||
| Net income (loss) |
$ | 8,347 | $ | (12,859,887 | ) | |||
| Adjustments to reconcile net income (loss) to net cash used in operating activities: |
||||||||
| Amortization of financing costs charged to interest expense |
190,305 | 98,961 | ||||||
| Depreciation and amortization |
167,791 | 238,048 | ||||||
| Minority interest |
(2,162 | ) | | |||||
| Goodwill impairment loss and intangible assets charge |
| 12,468,212 | ||||||
| Bad debt expense |
| 908,769 | ||||||
| Forgiveness of liability |
(501,561 | ) | | |||||
| Loss on disposal of assets |
2,227 | 1,121 | ||||||
| Increase in net deferred income tax asset |
| (369,135 | ) | |||||
| Changes in operating assets and liabilities, net of acquisition: |
||||||||
| Accounts receivable, net |
(2,290,149 | ) | (3,848,399 | ) | ||||
| Inventory |
3,529,905 | 2,787,821 | ||||||
| Due from affiliates |
10,470 | 593 | ||||||
| Prepaid expense and other current assets |
(580,744 | ) | (1,060,307 | ) | ||||
| Other assets |
8,525 | 2,780 | ||||||
| Patents and trademarks |
(3,034 | ) | | |||||
| Shareholder notes receivable |
78,723 | | ||||||
| Notes receivable |
129,157 | 135,833 | ||||||
| Deposits |
(42,400 | ) | (4,608 | ) | ||||
| Accounts payable |
(5,630,596 | ) | 480,383 | |||||
| Accrued expenses and other current liabilities |
(79,994 | ) | 234,020 | |||||
| Net cash used in operating activities |
(5,005,190 | ) | (785,795 | ) | ||||
| Cash flows from investing activities: |
||||||||
| Purchases of property and equipment |
(248,120 | ) | (36,159 | ) | ||||
| Proceeds from sale of property and equipment |
| 2,756 | ||||||
| Cash paid for acquisition of Avery |
(34,071 | ) | | |||||
| Net cash used in investing activities |
(282,191 | ) | (33,403 | ) | ||||